Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dermatophagoides pteronyssinus (Dpt) extract is an allergenic extract derived from the European house dust mite. It is a biological product used for allergen-specific immunotherapy (AIT) to treat allergic diseases in individuals sensitized to this common indoor allergen. [28, 30] AIT with Dpt extract is indicated for allergic rhinitis, allergic conjunctivitis, and allergic asthma. [12, 28] It has also been studied for its efficacy in atopic dermatitis. [30, 32] The therapy works by gradually administering increasing doses of the allergen to induce immune tolerance. This process shifts the body's immune response from a pro-allergic Th2-dominant state (characterized by IgE and inflammatory cytokines like IL-4 and IL-13) to a more tolerant Th1/Treg-dominant state. This modulation leads to the production of blocking antibodies (specifically IgG4), the induction of regulatory T-cells, and a reduction in the inflammatory response upon natural exposure to house dust mites. [12] The extract is administered either through subcutaneous injections (SCIT) or sublingually (SLIT) as tablets or solutions. [13, 18] It is also used as a diagnostic agent in skin prick tests to confirm sensitization. [26]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dermatophagoides pteronyssinus extract.